The Joint British Diabetes Societies (JBDS) for Inpatient Care group was created in 2008 to ‘deliver a set of diabetes inpatient guidelines and proposed standards of care within secondary care organisations’, with the overall aim of improving inpatient diabetes care through the development and use of high quality evidence based guidelines, and through better inpatient care pathways.
Commencement of the ABCD worldwide audit of testosterone deficiency in men with type 2 diabetes was held up by the recent COVID-19 pandemic surge. With the subsiding of that surge, ABCD would now like to invite you to join the audit.
DTN has developed the following guidance on defining high quality of care.
The ABCD Diabetes and COVID National Diabetes Audit is still live. We have now published 2 papers:
We are proud to launch a new grant funding scheme from The Association of British Clinical Diabetologists and The Diabetes Care Trust for high quality clinically based studies costing upto £50,000. We would particularly like to encourage applications from those at an earlier stage of their clinical and academic training, and clinical projects relating to the management and care of people with diabetes.
In the final webinar in this series focusing on obesity, hosted by ABCD and GIRFT and supported by Novo Nordisk Ltd, this session brings together experienced Physician, GP and surgical colleagues for expert case discussions to aid colleagues managing people with obesity across healthcare sectors.
Would you be interested in being a research centre for a clinical trial of a culturally-tailored T2D self-management programme for Black African-Caribbean adults?
People with diabetes on haemodialysis represent a complex group that are at high-risk for medical complications including hypoglycaemia. Furthermore, these individuals have historically not received the attention to their glycaemic control that would be required for their long-term health and expected according to guidelines for managing people with diabetes. The glycaemic assessment of individuals on haemodialysis is difficult to interpret owing to inaccuracies in commonly used measures of glycaemia.
Canagliflozin, Empagliflozin and Dapagliflozin audits
